Skip to main content

Table 1 Baseline characteristics of the RNOP-09 cohort as compared to the patients enrolled into the EORTC 26981/NCIC-CE.3 trial.

From: RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study

Baseline characteristics
  Treatment
  RNOP-09
(N = 63)
EORTC/NCI-C/NCI-C
(N = 287)
  N (%) N (%)
Sex   
   Female 23 (36.5) 102 (35.5)
   Male 40 (63.5) 185 (64.5)
Age (class)   
   <= 50 19 (30.2) 95 (33.1)
   51-60 19 (30.2) 109 (38.0)
   >60 25 (39.7) 83 (28.9)
Performance status (KPS)   
   90-100% 22 (34.9) 113 (39.4)
   80% 33 (52.4) 136 (47.4)
   70% 8 (12.7) 38 (13.2)
Extent of surgery   
   Complete 28 (44.4) 113 (39.4)
   Partial 23 (36.5) 126 (43.9)
   Biopsy 9 (14.3) 48 (16.7)
   Not recorded 3 (4.8) 0 (0.0)
Corticosteroids at study entry   
   No 39 (61.9) 94 (32.8)
   Yes 18 (28.6) 193 (67.2)
   Missing data 6 (9.5) 0 (0.0)
MGMT promoter   
   Methylated 16 (25.4) 46 (16.0)
   Unmethylated 17 (27.0) 60 (20.9)
   Missing 30 (47.6) 181 (63.1)
Survival at evaluation   
   Alive 22 (34.9) 33 (11.5)
   Dead 41 (65.1) 254 (88.5)
Progression free survival at evaluation   
   Not progressive and alive 7 (11.1) 15 (5.2)
   Progressive or dead 56 (88.9) 272 (94.8)